Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Xuzhou, China Clinical Trials

A listing of Xuzhou, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

This is a Phase II, randomized, multicenter, 2-arm, open-label clinical trial designed to compare the safety and efficacy of RC48-ADC with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), ...

Phase

0.0 miles

Learn More »

Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients

This is a dose finding trial. Totally 120 mild-moderate essential hypertension patients will be enrolled. All the patients will be randomized (1:1:1:1) into four groups (SPH3127 50mg, SPH3127 100mg, SPH3127 200mg and placebo). The trial has three phases: the screening phase, the leading phase and the treating phase. The primary ...

Phase

0.0 miles

Learn More »

Chinese Herbal Medicine and Micronized Progesterone for Threatened Miscarriage RCT

The causes of spontaneous miscarriage are diverse and comprise chromosomal, genetic, anatomical, immunological, hormonal, infectious and psychological factors, the other factors contribute to an increased risk include advancing paternal and maternal age and mothers with systemic diseases, such as diabetes or thyroid dysfunction. However, the incidence is difficult to determine ...

Phase

0.0 miles

Learn More »

Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL NOS

The prognosis of EBV+ DLBCL is dismal. Previous study showed that high level of PD-L1 expression in EBV+ DLBCL. The investigators therefore design this phase II study to investigate the safety and efficacy of sintilimab (an anti-PD-1 antibody) in combination with R-CHOP in patients with treatment-naive EBV+ DLBCL.

Phase

6.14 miles

Learn More »